Physician profile
Sukhween Kaur Patrick
NPI 1285285924
$2,539.83
in general payments reported to CMS, 2019-2025
26 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.60 · 2023: $234 · 2024: $1,125 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,393 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,392.70 |
| Education | $115.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.54 | 2023-2025 | |
| Amgen INC. | $545.72 | 2023-2025 | Krystexxa, Evenity, Prolia |
| Janssen Biotech, INC. | $438.53 | 2024-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $122.59 | 2024-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $107.62 | 2023-2025 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $71.90 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.88 | 2023-2025 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $52.20 | 2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $48.41 | 2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $43.54 | 2023-2024 | Lupkynis |
| Kiniksa Pharmaceuticals International, Plc | $41.18 | 2024 | Arcalyst |
| Octapharma USA, INC. | $41.10 | 2025 | Octagam Immune Globulin (Human) |
| Ani Pharmaceuticals, INC. | $40.94 | 2025 | Purified Cortrophin Gel |
| Sobi, INC | $40.93 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $34.48 | 2025 | Strensiq, Ultomiris |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $33.33 | 2024 | Acthar |
| Genentech USA, INC. | $31.60 | 2021 | |
| Sandoz INC. | $26.14 | 2025 | Jubbonti |
| Celgene Corporation | $22.71 | 2024 | Orencia |
| Vertex Pharmaceuticals Incorporated | $17.52 | 2025 | |
| Csl Behring | $17.46 | 2023 | Hizentra |
| Celltrion USA INC. | $16.53 | 2023 | Yuflyma |
| Glaxosmithkline, LLC. | $16.17 | 2025 | Benlysta |
| Tonix Medicines, INC. | $15.12 | 2025 | Tonmya |
| Actelion Pharmaceuticals US, INC. | $14.77 | 2024 | Opsumit, Uptravi |
| Scilex Pharmaceuticals INC. | $13.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukhween Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.